Full text is available at the source.
Abstract
Semaglutide is a GLP-1 receptor agonist approved for chronic weight management in eligible adults.
- Obesity presents substantial obstacles to achieving sustained weight loss through diet and exercise alone.
- GLP-1 receptor agonists like semaglutide may offer a pharmacological option for individuals struggling with obesity.
- Semaglutide is associated with improved weight management outcomes for eligible adults.
Simplified